Interactive Features

Quiz

Treating JAK-Naive Patients With Myelofibrosis With Pelabresib Plus Ruxolitinib

01/05/2024

What was the key finding of the MANIFEST-2 trial on the combination of pelabresib and ruxolitinib among patients with JAK-naïve myelofibrosis?

What was the key finding of the...

01/05/2024

Oncology

Quiz

Impact of Inflammatory Comorbidities on Myelofibrosis Disease Risk

01/05/2024

True or False: According to a retrospective analysis of younger patients with myelofibrosis (MF), inflammatory comorbidities were correlated with increased disease risk and decreased survival.

True or False: According to a...

01/05/2024

Oncology

Quiz

Treating Myelofibrosis With Pacritinib

12/06/2023

True or False: Pacritinib demonstrated consistent efficacy for spleen and symptom response among patients with myelofibrosis (MF), regardless of cytopenias.

True or False: Pacritinib...

12/06/2023

Oncology

Quiz

Non-JAK-Inhibitor Agents for Myelofibrosis

12/05/2023

____ is a non-JAK-inhibitor agent that has shown promise in the treatment landscape of myelofibrosis.

____ is a non-JAK-inhibitor...

12/05/2023

Oncology

Quiz

JAK Inhibitor Momelotinib for Myelofibrosis

11/28/2023

True or False: Results of the MOMENTUM study indicated that momelotinib showed benefits in symptom improvement, spleen improvement, and anemia among patients with myelofibrosis.

True or False: Results of the...

11/28/2023

Oncology

Quiz

Treating Myelofibrosis With Low-Dose Splenic Radiotherapy

11/28/2023

True or False: According to a retrospective institutional review, low-dose splenic radiotherapy in combination with allogeneic hematopoietic stem cell transplantation improved symptoms of splenomegaly and had encouraging safety outcomes among...

True or False: According to a...

11/28/2023

Oncology

Quiz

Quiz: BMS-986158 Plus Ruxolitinib or Fedratinib as Combination Treatment for Myelofibrosis

03/13/2023

True or False: In a study evaluating the safety and efficacy of BMS-986158 plus JAK inhibitors ruxolitinib or fedratinib for myelofibrosis, no serious treatment-related adverse events led to treatment discontinuation among patients who...

True or False: In a study...

03/13/2023

Oncology

Quiz

Quiz: Momelotinib in Symptomatic and Anemic Myelofibrosis Patients Previously Treated With a JAK Inhibitor

12/07/2022

True or false: Momelotinib improved symptom responses, transfusion requirements, and spleen responses in symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol with comparable safety...

True or false: Momelotinib...

12/07/2022

Oncology

Quiz

Quiz: Total Symptom Score of Momelotinib vs Danazol in Patients With Myelofibrosis

11/08/2022

Quiz: Momelotinib was found to be superior to danazol in patients with symptomatic, anemic, and thrombocytopenic myelofibrosis for symptom responses, according to a phase 3 trial. What was the total symptom score response rate with...

Quiz: Momelotinib was found to...

11/08/2022

Oncology

Quiz

Tolerability of Jaktinib in JAK Inhibitor-Naïve Patients with Myelofibrosis

10/05/2022

True or False: According to a recent study, jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis.

True or False: According to a...

10/05/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology